Financial Burden on Cancer Patients: High Out-of-Pocket Costs Post-Diagnosis
A new study reveals that cancer patients face increasing out-of-pocket costs after diagnosis, especially with advanced stages, emphasizing the need for supportive policies to ease financial stress.
A recent study highlights the significant financial challenges faced by patients diagnosed with cancer, with out-of-pocket costs (OOPCs) rising sharply after initial diagnosis. The research, published in JAMA Network Open, finds that patients experience an average increase of nearly $593 per month in medical expenses during the first six months following diagnosis. Notably, the costs escalate with the stage of cancer at diagnosis, ranging from approximately $462 for early-stage (stage 0) to nearly $720 for advanced stages (stage 4).
Liam Rose, Ph.D., and colleagues from Stanford University conducted a comprehensive retrospective cohort study involving over 46,000 privately insured individuals under 65 years old, including patients with breast, colorectal, and lung cancers. The study compared their expenses to those of a control group without cancer. Findings emphasized that more advanced cancers correlate with higher out-of-pocket costs, underscoring the financial strain imposed on patients.
The authors suggest that policies such as paid sick leave and enhanced financial assistance could help alleviate some of these burdens, especially for those with late-stage cancer. Addressing insurance continuity and out-of-pocket expenses is crucial for supporting patients during this challenging time.
This research provides vital insights into the economic impact of cancer diagnosis and highlights the need for comprehensive policies to reduce financial toxicity for patients. source
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Herpes Virus Engineered to Fight Advanced Melanoma Shows Promising Results
A groundbreaking study demonstrates that a genetically engineered herpes simplex virus shows promising results in treating advanced melanoma, especially those resistant to immunotherapy, offering new hope for patients worldwide.
Maintenance Combination of Lurbinectedin and Atezolizumab Improves Survival in Lung Small Cell Carcinoma
A combination of lurbinectedin and atezolizumab as maintenance therapy significantly improves survival in extensive-stage small cell lung cancer, according to new research presented at ASCO 2025.
Study Finds Watching Others Eat Can Encourage Overeating in Mice
New research presented at ENDO 2025 demonstrates that mice tend to eat more when they see others consuming tasty foods, revealing social and visual cues as factors in overeating. The study highlights the brain's reward system as a target for future obesity treatments.
Potential Medicare Savings of $3.6 Billion by Reducing Low-Value Services, Study Finds
A groundbreaking study suggests Medicare could save $3.6 billion annually by reducing low-value services that offer little benefit or pose risks to older adults, promoting more efficient and safer healthcare practices.